Early clinical response as a predictor of subsequent response to ixekizumab treatment: Results from a phase II study of patients with moderate-to-severe plaque psoriasis

British Journal of Dermatology

Volumn 169, Issue 6, 2013, Pages 1337-1341

  Zhu, B ^a   Edson Heredia, E ^a   Cameron, G S ^a   Shen, W ^a   Erickson, J ^a   Shrom, D ^a   Wang, P ^a   Banerjee, S ^a   Gordon, K B ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IXEKIZUMAB; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; TREATMENT RESPONSE; CLINICAL TRIAL; DOSE RESPONSE; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PSORIASIS; ROC CURVE; TREATMENT OUTCOME;

EID: 84887968942     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12610     Document Type: Article

References (9)

1. van der Heijde D, Keystone EC, Curtis JR, et al,. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 2012; 39: 1326-33.
2. Aletaha D, Funovits J, Keystone EC, Smolen JS,. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56: 3226-35.
3. Ichikawa Y, Saito T, Yamanaka H, et al,. Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. J Rheumatol 2010; 37: 723-9.
4. van VR, Krishnaswami S, Benda B, et al,. Tofacitinib and adalimumab achieve similar rates of low disease activity in rheumatoid arthritis-lack of improvement in disease activity score by 3 months predicts low likelihood of low disease activity at 1 year. Arthritis Rheum 2012; 64 (Suppl. 10): 1297. (abstract).
5. Saurat JH, Langley RG, Reich K, et al,. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol 2011; 165: 399-406.
6. Leonardi C, Matheson R, Zachariae C, et al,. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
7. Leonardi C,. Response to brodalumab and ixekizumab, anti-interleukin-17- receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol 2012; 167: 714-15.
8. Staidle JP, Dabade TS, Feldman SR,. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011; 12: 2041-54.
9. Ryan C, Abramson A, Patel M, Menter A,. Current investigational drugs in psoriasis. Expert Opin Investig Drugs 2012; 21: 473-87.